Chemical genomics versus orthodox drug development

Drug Discovery Today

Volumn 8, Issue 4, 2003, Pages 157-159

  Szymkowski, David E ^a  

^a Xencor Inc   (United States)

Author keywords

Chemical genomics; Drug Discovery; Drugs; Molecular Medicine; Pharmaceutical Science; Targets

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; PARACETAMOL; ROFECOXIB; SALICIN; SALICYLIC ACID DERIVATIVE;

BIOCHEMISTRY; BIOTECHNOLOGY; CAENORHABDITIS ELEGANS; CHEMICAL GENETICS; CONFERENCE PAPER; DRUG COST; DRUG EFFECT; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; EXPERIMENTAL MODEL; GENE EXPRESSION; GENOMICS; NONHUMAN;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; DRUG INDUSTRY; GENE EXPRESSION PROFILING; GENOME, HUMAN; GENOMICS; HUMANS;

EID: 0037441526     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02599-6     Document Type: Conference Paper

References (4)

1. Vane J.R., et al. History of aspirin and its mechanism of action. Stroke. 21:(Suppl. 12):2002;12-23.
2. Chandrasekharan N.V., et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. U. S. A. 99:2002;13926-13931.
3. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23:1997;3-25.
4. Steinmetz L.M., et al. Systematic screen for human disease genes in yeast. Nat. Genet. 31:2002;400-404.